ABVC BioPharma (NASDAQ:ABVC) Stock Price Down 3.4% – Time to Sell?

ABVC BioPharma, Inc. (NASDAQ:ABVC)’s stock price was down 3.4% during trading on Thursday . The stock traded as low as $1.11 and last traded at $1.14. Approximately 49,807 shares changed hands during trading, a decline of 66% from the average daily volume of 146,310 shares. The stock had previously closed at $1.18.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

ABVC BioPharma Stock Performance

The company has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $2.06. The stock has a market capitalization of $29.00 million, a price-to-earnings ratio of -2.85 and a beta of 0.38.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.11) earnings per share for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of ABVC BioPharma by 5.8% in the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after purchasing an additional 6,017 shares during the period. Citadel Advisors LLC bought a new stake in shares of ABVC BioPharma in the 3rd quarter valued at $48,000. Finally, Millennium Management LLC acquired a new stake in shares of ABVC BioPharma during the third quarter worth $60,000. Institutional investors own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.